42753-75-3 Usage
Description
METHYL 5-AMINOSALICYLATE, also known as 5-Amino-2-hydroxybenzoic Acid Methyl Ester, is a disubstituted benzoic acid derivative with significant potential in the pharmaceutical industry. It is characterized by its unique chemical structure, which allows it to be utilized in the development of various pharmaceutical compounds.
Uses
Used in Pharmaceutical Industry:
METHYL 5-AMINOSALICYLATE is used as a key intermediate compound for the synthesis of various pharmaceutical compounds, particularly sphingosine kinase inhibitors. These inhibitors play a crucial role in the treatment of various diseases, including cancer, inflammatory disorders, and neurodegenerative conditions, by targeting the sphingosine kinase enzyme and modulating its activity.
In the development of sphingosine kinase inhibitors, METHYL 5-AMINOSALICYLATE serves as a building block, providing the necessary structural framework for the design and synthesis of potent and selective inhibitors. These inhibitors can potentially be used in the treatment of a wide range of diseases by modulating the sphingolipid signaling pathway, which is often dysregulated in various pathological conditions.
Furthermore, METHYL 5-AMINOSALICYLATE may also find applications in other areas of the pharmaceutical industry, such as the development of novel drugs targeting different enzymes or receptors, or as a component in the synthesis of complex drug molecules with multiple therapeutic targets.
Check Digit Verification of cas no
The CAS Registry Mumber 42753-75-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,2,7,5 and 3 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 42753-75:
(7*4)+(6*2)+(5*7)+(4*5)+(3*3)+(2*7)+(1*5)=123
123 % 10 = 3
So 42753-75-3 is a valid CAS Registry Number.
InChI:InChI=1/C8H9NO3/c1-12-8(11)6-4-5(9)2-3-7(6)10/h2-4,10H,9H2,1H3
42753-75-3Relevant articles and documents
Inhibition of 3D colon cancer stem cell spheroids by cytotoxic RuII-p-cymene complexes of mesalazine derivatives
Acharya, Sourav,Ghosh, Subhashis,Maji, Moumita,Mukherjee, Arindam,Parambil, Ajmal Roshan Unniram,Singh, Sandeep
, p. 5421 - 5424 (2020)
The Ru(ii) complex of an imidazole-mesalazine Schiff base is a unique example showing growth inhibition of 3D-colon cancer stem cell spheroids and bulk colon cancer cells at lower dosage than salinomycin or oxaliplatin. Unlike oxaliplatin which increases
MODIFIED PROTEINS AND PROTEIN DEGRADERS
-
Paragraph 00308-00310, (2021/12/08)
Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are compounds having a DNA damage-binding protein 1 (DDB1) binding moiety. Some such embodiments include a linker. Some such embodiments include a target protein binding moiety. Further provided herein are ligand-DDB1 complexes. Further provided herein are in vivo modified DDB1 proteins.
PYROPTOSIS-INDUCED IMMUNOTHERAPY
-
Paragraph 041; 074, (2021/03/05)
Pyroptosis-induced immunotherapy is effected by activating a pore-forming, pyrpotogenic molecule, wherein the activating induces tumor cell pryoptosis and causes tumor regression by T-cell mediated anti-tumor immunity.
